Merck

YTD

ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.

CEO

Robert M. Davis

CEORobert M. Davis

Employees

75,000

Employees75,000

Headquarters

Rahway, New Jersey

HeadquartersRahway, New Jersey

Founded

1891

Founded1891

Employees

75,000

Employees75,000

MRK Key Statistics

Market cap

197.31B

Market cap197.31B

Price-Earnings ratio

11.64

Price-Earnings ratio11.64

Dividend yield

4.03%

Dividend yield4.03%

Average volume

18.38M

Average volume18.38M

High today

$78.71

High today$78.71

Low today

$78.59

Low today$78.59

Open price

$79.50

Open price$79.50

Volume

10.94K

Volume10.94K

52 Week high

$134.63

52 Week high$134.63

52 Week low

$75.96

52 Week low$75.96

MRK News

Benzinga 18h

Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery

Merck & Co Inc MRK and privately held Cyprumed GmbH signed a non-exclusive license and option agreement on Tuesday to develop oral formulations of Merck's pepti...

TipRanks 5d

MRK Lawsuit Alert! Class Action Lawsuit Against Merck & Company

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs (shareholders) alleged that they bought MRK...

Simply Wall St 6d

Merck Faces Multiple Shareholder Proposals Ahead Of Annual Meeting

recently experienced a significant corporate governance event when multiple shareholder proposals were announced, with the company recommending against them for...

Analyst ratings

65%

of 26 ratings

Buy

65.4%

Hold

34.6%

Sell